bispecific T-cell engager

…engager drugs (also known as bispecific T-cell engagers, or BiTEs), designed to target specific tumor-associated antigens, have shown promise against prostate cancer. In addition, experimental, minimally invasive modalities, such as sonodynamic therapy, can potentially enhance the effectiveness of other treatments, including ultrasound-induced cell death.